Development of Intracellular Drug Delivery Technology Using Functional Peptides in Boron Neutron Capture Therapy
MEMBRANE · 2026 · 51 (2) · 93-98
DOI: 10.5360/membrane.51.93 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEMBRANE, 2026. Verfasst von Ikuhiko Nakase und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Boron Neutron Capture Therapy (BNCT) involves introducing non–cytotoxic boron–10 atoms into cancer cells, followed by irradiation with low–energy thermal neutrons. This process causes the boron–10 atoms to undergo neutron capture reactions within the cells, releasing high–energy particles (this causes nuclear transmutation reactions within the cells, producing alpha particles and lithium recoil nuclei) that induce the cancer cell–killing activity. Our research team has been working on developing intracellular delivery technology for functional peptide–based boron compounds that can target organelles, aiming to contribute to improving the aforementioned challenges of BNCT, albeit through basic research. Furthermore, we have also developed carrier technology that incorporates exosomes– cell–secreted vesicles–as a new material. Although still in vitro experiments, we have successfully developed a method capable of efficiently inducing cancer cell death using low concentrations of boron compounds.
Zitieren
APA
Nakase, I., & Hattori, Y. (2026). Development of Intracellular Drug Delivery Technology Using Functional Peptides in Boron Neutron Capture Therapy. MEMBRANE, 51(2), 93-98. https://doi.org/10.5360/membrane.51.93
Vancouver
Nakase I, Hattori Y. Development of Intracellular Drug Delivery Technology Using Functional Peptides in Boron Neutron Capture Therapy. MEMBRANE. 2026;51(2):93-98. doi:10.5360/membrane.51.93
BibTeX
@article{Nakase2026,
author = {Nakase, Ikuhiko and Hattori, Yoshihide},
title = {Development of Intracellular Drug Delivery Technology Using Functional Peptides in Boron Neutron Capture Therapy},
journal = {MEMBRANE},
year = {2026},
volume = {51},
number = {2},
pages = {93--98},
doi = {10.5360/membrane.51.93}
}
EUVIMED